Abstract
Ovarian cancer possesses metabolic properties typical for any malignancy as well as some specific characteristics. Most of the methodological approach to study metabolism and molecular composition of the living cells are suitable for ovarian cancer research, however, might require minor modifications. The chapter reviews various laboratory techniques adapted to study ovarian cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674
Warburg O (1956) On the origin of cancer cells. Science 123:309–314
Martinez-Outschoorn UE, Sotgia F, Lisanti MP (2012) Power surge: supporting cells “fuel” cancer cell mitochondria. Cell Metab 15:4–5
Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R et al (2011) Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 17:1498–1503
Gercel-Taylor C, Doering DL, Kraemer FB, Taylor DD (1996) Aberrations in normal systemic lipid metabolism in ovarian cancer patients. Gynecol Oncol 60:35–41
Fong MY, McDunn J, Kakar SS (2011) Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer. PLoS One 6:e19963
Iorio E, Ricci A, Bagnoli M, Pisanu ME, Castellano G et al (2010) Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res 70:2126–2135
Shield K, Ackland ML, Ahmed N, Rice GE (2009) Multicellular spheroids in ovarian cancer metastases: biology and pathology. Gynecol Oncol 113:143–148
Kwon Y, Cukierman E, Godwin AK (2011) Differential expressions of adhesive molecules and proteases define mechanisms of ovarian tumor cell matrix penetration/invasion. PLoS One 6:e18872
Zhang Y, Xu B, Liu Y, Yao H, Lu N et al (2012) The ovarian cancer-derived secretory/releasing proteome: a repertoire of tumor markers. Proteomics 12:1883–1891
Wang LN, Tong SW, Hu HD, Ye F, Li SL et al (2012) Quantitative proteome analysis of ovarian cancer tissues using a iTRAQ approach. J Cell Biochem 113:3762–3772
Sinclair J, Metodieva G, Dafou D, Gayther SA, Timms JF (2011) Profiling signatures of ovarian cancer tumour suppression using 2D-DIGE and 2D-LC-MS/MS with tandem mass tagging. J Proteomics 74:451–465
Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D et al (2009) Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer 100:134–144
Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D et al (2005) Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 4:346–355
Irie HY, Shrestha Y, Selfors LM, Frye F, Iida N et al (2010) PTK6 regulates IGF-1-induced anchorage-independent survival. PLoS One 5:e11729
Carey MS, Agarwal R, Gilks B, Swenerton K, Kalloger S et al (2010) Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res 16:2852–2860
Krueger KE, Srivastava S (2006) Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics. Mol Cell Proteomics 5:1799–1810
Seo JH, Jeong KJ, Oh WJ, Sul HJ, Sohn JS et al (2010) Lysophosphatidic acid induces STAT3 phosphorylation and ovarian cancer cell motility: their inhibition by curcumin. Cancer Lett 288:50–56
Chao H, Wang L, Hao J, Ni J, Graham PH et al (2013) Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway. Cancer Lett 329(1):17–26
Tomek K, Wagner R, Varga F, Singer CF, Karlic H et al (2011) Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer. Mol Cancer Res 9:1767–1779
John Wiley & Sons I (2010) Post-translation modification. http://www.currentprotocols.com/WileyCDA/CurPro3Category/L1-3600,L2-3621.html
National Cancer Institute SFS (2011) http://seer.cancer.gov/statfacts/html/ovary.html
Alley WR Jr, Vasseur JA, Goetz JA, Svoboda M, Mann BF et al (2012) N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. J Proteome Res 11:2282–2300
Wu J, Xie X, Liu Y, He J, Benitez R et al (2012) Identification and confirmation of differentially expressed fucosylated glycoproteins in the serum of ovarian cancer patients using a lectin array and LC-MS/MS. J Proteome Res 11:4541–4552
Mechref Y, Hu Y, Garcia A, Hussein A (2012) Identifying cancer biomarkers by mass spectrometry-based glycomics. Electrophoresis 33:1755–1767
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, New York
About this protocol
Cite this protocol
Malek, A. (2013). Energy Metabolism and Changes in Cellular Composition in Ovarian Cancer. In: Malek, A., Tchernitsa, O. (eds) Ovarian Cancer. Methods in Molecular Biology, vol 1049. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-547-7_17
Download citation
DOI: https://doi.org/10.1007/978-1-62703-547-7_17
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-546-0
Online ISBN: 978-1-62703-547-7
eBook Packages: Springer Protocols